{
    "clinical_study": {
        "@rank": "55368", 
        "arm_group": [
            {
                "arm_group_label": "Group I (observation)", 
                "arm_group_type": "No Intervention", 
                "description": "Patients undergo observation."
            }, 
            {
                "arm_group_label": "Group II (metformin hydrochloride)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive metformin hydrochloride PO BID for at least 7 days in the absence of disease progression or unacceptable toxicity."
            }, 
            {
                "arm_group_label": "Group III (metformin hydrochloride)", 
                "arm_group_type": "Experimental", 
                "description": "Patients receive metformin hydrochloride as in Group II."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized clinical trial studies metformin hydrochloride in treating patients with\n      pancreatic cancer that can be removed by surgery. Metformin hydrochloride may stop the\n      growth of tumor cells by blocking some of the enzymes needed for cell growth."
        }, 
        "brief_title": "Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stage IA Pancreatic Cancer", 
            "Stage IB Pancreatic Cancer", 
            "Stage IIA Pancreatic Cancer", 
            "Stage IIB Pancreatic Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Pancreatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the effect of escalating doses of metformin (metformin hydrochloride) given\n      pre-operatively on pancreatic cancer cell proliferation and apoptosis.\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess toxicity of escalating doses of metformin given pre-operatively in patients\n      with resectable pancreatic carcinoma.\n\n      II. To measure the effect of metformin on the expression of phosphorylated acetyl-CoA\n      carboxylase alpha (ACC), phosphorylated mechanistic target of rapamycin (serine/threonine\n      kinase) (mTOR), and pancreatic cancer stem cells.\n\n      OUTLINE: Patients are randomized to 1 of 3 treatment groups.\n\n      GROUP I: Patients undergo observation.\n\n      GROUP II: Patients receive metformin hydrochloride orally (PO) twice daily (BID) for at\n      least 7 days in the absence of disease progression or unacceptable toxicity.\n\n      GROUP III: Patients receive metformin hydrochloride as in Group II.\n\n      After completion of study treatment, patients are followed up 30 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed resectable pancreatic\n             carcinoma; patients with pancreatic neuroendocrine tumors are not eligible\n\n          -  Patients must be previously untreated with chemotherapy or radiation therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n\n          -  Patients must have surgical resection of the pancreas planned, with enrollment at\n             least 7 days prior to surgery; patients with surgery scheduled > 15 days will not be\n             excluded\n\n          -  Hemoglobin (Hg)A1C must be below 7%\n\n          -  Total bilirubin less than 1.5 X institutional upper limit of normal\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =<\n             2.5 X institutional upper limit of normal\n\n          -  Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5\n             X institutional upper limit of normal\n\n          -  Serum creatinine within normal institutional limits\n\n          -  Alkaline phosphatase < 1.5 X institutional upper limit of normal\n\n          -  Subjects must have the ability to understand and be willing to provide written\n             informed consent\n\n        Exclusion Criteria:\n\n          -  History of metformin use in the previous 3 months\n\n          -  Treatment with neoadjuvant chemotherapy or radiation therapy\n\n          -  History of allergic reactions attributed to metformin\n\n          -  Patients with uncontrolled intercurrent illness including, but not limited to ongoing\n             or active infection, symptomatic congestive heart failure, unstable angina pectoris,\n             cardiac arrhythmia, or psychiatric illness/social situations that would limit\n             compliance with study requirements\n\n          -  Metabolic acidosis, acute or chronic, including ketoacidosis\n\n          -  Metastatic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954732", 
            "org_study_id": "CASE1213", 
            "secondary_id": [
                "NCI-2013-01836", 
                "CASE 1213", 
                "P30CA043703"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group II (metformin hydrochloride)", 
                    "Group III (metformin hydrochloride)"
                ], 
                "description": "Given PO", 
                "intervention_name": "metformin hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": "Glucophage"
            }, 
            {
                "arm_group_label": [
                    "Group II (metformin hydrochloride)", 
                    "Group III (metformin hydrochloride)"
                ], 
                "description": "Correlative studies", 
                "intervention_name": "pharmacological study", 
                "intervention_type": "Other", 
                "other_name": "pharmacological studies"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Neal.Meropol@uhhospitals.org", 
                    "last_name": "Neal J. Meropol, MD", 
                    "phone": "216-844-5220"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106-5065"
                    }, 
                    "name": "Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Neal J. Meropol", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Estfanb@ccf.org", 
                    "last_name": "Bassam N. Estfan, MD", 
                    "phone": "216-445-9449"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Bassam N. Estfan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer", 
        "overall_official": {
            "affiliation": "Case Comprehensive Cancer Center", 
            "last_name": "Neal Meropol, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The difference between treatment groups will be compared using analysis of variance (ANOVA) (3 groups) followed by Tukey's pair-wise comparison procedure. Transformation may be applied (e.g. natural log) prior to analysis to better approximate normality.", 
            "measure": "Pancreatic tumor cell proliferation and apoptosis as measured by the percentage of cells Ki-67+, percentage of cells TUNEL+, and mitotic counts in tissue samples", 
            "safety_issue": "No", 
            "time_frame": "At time of surgery (after 7 days of treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954732"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Will be summarized as the percentage of patients by type and grade according to treatment group.", 
                "measure": "Occurrence of grade 3 and 4 toxicities according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE; version 4.0)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 30 days after treatment has been discontinued or after the date of surgery, whichever occurs first"
            }, 
            {
                "description": "The difference between treatment groups will be compared using ANOVA followed by Tukey's pair-wise comparison procedure. Laser scanning cytometry and iCyte software used to quantify the MFI of pACC and pMTOR.", 
                "measure": "Expression of pACC and pMTOR quantified by the mean fluorescence intensity (MFI) in tissue samples", 
                "safety_issue": "No", 
                "time_frame": "At time of surgery (after 7 days of treatment)"
            }, 
            {
                "description": "For each of biologic biomarkers (pACC, pMTOR, CD44+CD24+ESA+ cells), the difference between treatment groups will be compared using ANOVA (3 groups) followed by Tukey's pair-wise comparison procedure. Transformation may be applied (e.g. natural log) prior to analysis to better approximate normality.", 
                "measure": "Percentage of pancreatic cancer stem cells in tissue samples", 
                "safety_issue": "No", 
                "time_frame": "At time of surgery (after 7 days of treatment)"
            }
        ], 
        "source": "Case Comprehensive Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Case Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}